These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
161 related items for PubMed ID: 3815730
1. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole. Markman M, Chan TC, Cleary S, Howell SB. Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730 [Abstract] [Full Text] [Related]
2. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate. Chan TC, Markman M, Cleary S, Howell SB. Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032 [Abstract] [Full Text] [Related]
3. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F. Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275 [Abstract] [Full Text] [Related]
4. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. Casper ES, Vale K, Williams LJ, Martin DS, Young CW. Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457 [Abstract] [Full Text] [Related]
6. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma. Casper ES, Baselga J, Smart TB, Magill GB, Markman M, Ranhosky A. Cancer Chemother Pharmacol; 1991 May; 28(1):51-4. PubMed ID: 2040033 [Abstract] [Full Text] [Related]
11. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group. Bramwell V, Van Oosterom A, Mouridsen HT, Cheix F, Somers R, Thomas D, Rozencweig M. Eur J Cancer Clin Oncol; 1982 Jan; 18(1):81-4. PubMed ID: 6211362 [Abstract] [Full Text] [Related]
16. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. Hageboutros A, Rogatko A, Newman EM, McAleer C, Brennan J, LaCreta FP, Hudes GR, Ozols RF, O'Dwyer PJ. Cancer Chemother Pharmacol; 1995 Jan; 35(3):205-12. PubMed ID: 7805178 [Abstract] [Full Text] [Related]
17. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A. Cancer; 1991 Sep 15; 68(6):1242-6. PubMed ID: 1873776 [Abstract] [Full Text] [Related]